Andrea C Gore, PhD, The University of Texas at Austin, Austin, TX
Dr. Andrea Gore is the Johnson & Johnson Centennial Professor of Pharmacology and Toxicology at the University of Texas at Austin. Her research focuses on understanding the neurobiological control of reproduction. Ongoing NIH-funded projects in the laboratory are investigating how environmental endocrine disruptors perturb the developing hypothalamus, and effects of estrogen on the aging brain in models of menopause. Dr. Gore has published 4 books and 124 papers related to these subjects. She is an internationally-recognized expert on neurobiological actions of endocrine disruptors on neurobiological and hormonal functions, and has participated in activities with the Endocrine Society and other organizations to increase scientific awareness of biological effects of EDCs. Dr. Gore has received many awards and honors, including election as Fellow of the American Association for the Advancement of Science. Dr. Gore is the Editor-in-chief of the journal Endocrinology.
Bryan R. Haugen, MD, University of Colorado Medical School, Aurora, CO
Bryan R. Haugen, MD is Professor of Medicine and Pathology at the University of Colorado Denver. He is also Chief of the Division of Endocrinology, Metabolism & Diabetes and Director of the Thyroid Tumor Program which monitors and manages more than 2500 patients with thyroid cancer. He currently holds the Marry Rossick Kern and Jerome H Kern Chair in Endocrine Neoplasms Research. Dr Haugen received is BA degree in Chemistry from Saint Olaf College and medical degree from the Mayo Medical School in 1987. Internship, medical residency and endocrine fellowship were completed at the University of Colorado Health Sciences Center. Dr Haugen is a Fellow in the American College of Physicians, and member of the Association of American Physicians (AAP), the American Thyroid Association (ATA), the Endocrine Society, the American Association of Clinical Endocrinologists and the American Society for Biochemistry and Molecular Biology. Dr Haugen is also the Past-President of the ATA and Chair of the ATA thyroid nodule and differentiated cancer guidelines task force. He has received the Paul Starr Award from the ATA for advancements in clinical thyroidology. His current clinical interests include thyroid neoplasms, advanced thyroid cancer, thyroid dysfunction and other endocrine tumors (parathyroid, adrenal, carcinoid). Dr Haugens research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets. Specific areas of research include nuclear hormone receptors (RXR, TR, PPAR) and kinase signaling pathways as therapeutic targets in thyroid cancer. Dr Haugen led validation of a novel molecular test (called Afirma, marketed by Veracyte, Inc) that can help avoid unnecessary surgery in certain patients with thyroid nodules. His research group is also actively studying the individual host-tumor interaction in thyroid cancer to develop novel tumor immunology tests and therapies.
Ronald N Cohen, MD, University of Chicago, Chicago, IL
Dr. Cohen obtained his MD degree from Cornell University Medical College, obtained his Internal Medicine and Endocrinology training at Beth Israel Deaconess Medical Center in Boston. After fellowship, he stayed on at Beth Israel Deaconess as Instructor in Medicine at Harvard Medical School. In 2000, Dr. Cohen was recruited to University of Chicago as Assistant Professor of Medicine, and was promoted to Associate Professor in 2007. In 2015, Dr. Cohen was appointed Chief of the Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism at University of Chicago. Dr. Cohen has won numerous awards, including the Quantrell Award for Excellence in Undergraduate Education at the University of Chicago. He is a standing member of the Molecular and Cellular Endocrinology Study Section of the NIH, and is a member of the Editorial Board of the Journal of Biological Chemistry. His research focuses on the role of nuclear receptors and coregulators in metabolism, and factors that influence adipocyte biology.
Sally A Camper, PhD, University of Michigan, Ann Arbor, MI
Professor Dept. of Human Genetics, University of Michigan, Ann Arbor, MI. Camper is recognized for research contributions in pituitary development and function and the genetics of birth defects. She uses classical and modern mouse genetics to establish gene function, reveal disease mechanisms and pathophysiology and assess therapeutic intervention. Ongoing work utilizes next generation sequencing to identify human patient mutations directly. She has published over 150 articles and has a continuous record of external funding, including an NIH Merit award. Camper is devoted to the educational mission of the university through didactic teaching and mentoring, including 5 years of service as Associate Director of the graduate Program in Biomedical Sciences, a common gateway for Ph.D. studies in thirteen different disciplines. Eighteen of her trainees hold faculty positions.
Daniel J. Bernard, PhD, McGill University, Montreal, Canada
Prof. Bernard earned his Ph.D. at Johns Hopkins University and then conducted post-doctoral research in molecular endocrinology at Northwestern University. His first independent position was as a Staff Scientist at the Population Council’s Center for Biomedical Research at The Rockefeller University. He then moved his lab to McGill in April 2006. The Bernard lab investigates molecular mechanisms of pituitary hormone synthesis using in vitro and in vivo approaches. Projects in the lab concern: 1) signal transduction mechanisms through which members of the transforming growth factor â superfamily regulate pituitary follicle-stimulating hormone (FSH) synthesis, 2) mechanisms of gonadotropin-releasing hormone (GnRH) signaling in pituitary gonadotrope cells, and 3) hypothalamic-pituitary control of thyroid hormone production.
Carol A Lange, PHD, Masonic Cancer Center, Minneapolis, MN
Dr. Lange holds the Tickle Family Land Grant Chair in Breast Cancer Research and is the Director of the U of MN Masonic Cancer Center Cell Signaling Program. She is also the Director of an NIH T32 Cancer Biology Training Grant. Dr. Lange works with human cell line and mouse models to understand mechanisms of cancer progression that involve signal transduction cross talk with steroid hormone receptors in breast, lung, and ovarian cancer models. She is an expert in signaling pathways acting upstream of mitogen-activated protein kinases (MAPKs) and the role of mitogenic protein kinases as major inputs to ligand-dependent and -independent progesterone receptor action and target gene selection in breast cancer. She also studies breast tumor kinase (Brk/PTK6) actions upstream of the ERK5 and p38 MAPK stress signaling pathways and their roles in breast tumor progression and hypoxia. These signaling molecules may be targeted as part of combination therapies aimed at halting tumor progression and metastasis.
CAL: Advisory Group Member, Celcuity. Nothing to Disclose: ACG, BRH, RNC, SAC, DJB
After this session, attendees will be able to:
- Understand the importance of each grant component, highlighting recent changes in NIH grant applications.
- Acknowledge key areas to effectively present their research.
- Understand what reviewers look for in NIH grants and similar research grant applications.